{"id":333803,"date":"2017-06-21T10:32:11","date_gmt":"2017-06-21T14:32:11","guid":{"rendered":"https:\/\/www.sciencedaily.com\/releases\/2017\/06\/170621103211.htm"},"modified":"2017-06-21T10:32:11","modified_gmt":"2017-06-21T14:32:11","slug":"new-inhibitor-drug-shows-promise-in-relapsed-leukemia","status":"publish","type":"post","link":"https:\/\/spaceweekly.com\/?p=333803","title":{"rendered":"New inhibitor drug shows promise in relapsed leukemia"},"content":{"rendered":"<p>A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers. In a first-in-human study, researchers treated relapsed patients with gilteritinib, an FLT3 inhibitor, and found it was a well-tolerated drug that led to frequent and more-sustained-than-expected clinical responses, almost exclusively in patients with this mutation. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers. In a first-in-human study, researchers treated relapsed patients with gilteritinib, an FLT3 inhib&#8230;<\/p>\n","protected":false},"author":61,"featured_media":615444,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-333803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/333803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/users\/61"}],"replies":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=333803"}],"version-history":[{"count":1,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/333803\/revisions"}],"predecessor-version":[{"id":333804,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/333803\/revisions\/333804"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/media\/615444"}],"wp:attachment":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=333803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=333803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=333803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}